pharmacokinetics in English
Methadone's unique pharmacokinetics and pharmacodynamics make it a valuable option in the management of cancer pain and other chronic pain, including neuropathic pain states.
Use "pharmacokinetics" in a sentence
1. Keywords: diazepam, mars, pharmacokinetics, elimination, Autointoxication
2. Pharmacokinetics and Asparagin e levels in
3. What drugs alter prothrombin time by interacting with warfarin levels ( pharmacokinetics )?
4. Anticoagulants: Pharmacokinetics, Mechanisms of Action, and Indications Neurosurg Clin N Am
5. Publication types Review MeSH terms Ampicillin / chemistry Ampicillin / pharmacokinetics Ampicillin / toxicity* Animals
6. OBJECTIVE To study pharmacokinetics and Bioequivalence of domperidone chewable tablets in healthy Chinese volunteers.
7. This video concisely describes Bioavailability and first pass metabolism - both important concepts in pharmacokinetics.
8. Alkaloids are divided into several classes based on their sources, pharmacokinetics and chemical structures
9. Dose adjustment can be derived from peak or trough levels according to accumulation pharmacokinetics.
10. Children The pharmacokinetics of oseltamivir have been evaluated in single-dose pharmacokinetic studies in children aged # to # years
11. 3.3.3 Pharmacokinetics Absorption Peak plasma levels of solifenacin were noted 3-8 hours after oral administration.
12. Age and gender Limited data on the pharmacokinetics of tenofovir in women indicate no major gender effect
13. 3.2.2 Pharmacokinetics Absorption Paliperidone was well absorbed in dogs and rats after oral administration of a paliperidone solution.
14. Of the four areas traditionally included in the area of pharmacokinetics, Absorption changes in the elderly are probably the least clinically important
15. (Nasdaq: BDSI) has initiated its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral® Amphotericin B
16. Solution to EXPAREL of 1:2 when Admixing, as this may impact the pharmacokinetics and/or physicochemical properties of the drugs (7)
17. 3.3.2 Pharmacokinetics One study was conducted to determine the PKs and PDs of multiple doses of efalizumab in the presence of adjunctive immunosuppressive agents.
18. Objective To investigate the effects of Szechwan Lovage Phizome combined with different proportions of Turmeric Root Tuber on the pharmacokinetics of ferulic acid(FA)in rabbits.
19. We investigated the pharmacokinetics of Alkalized intravesical lidocaine in healthy volunteers and patients with interstitial cystitis to determine a safe dose of buffered lidocaine
20. Pyrexia Thermoregulation Action of pyrogens Antipyretics What Antipyretics do here History of Antipyretics Types of drugs Ethnobotanical drugs Chemically synthesized drugs Pharmacokinetics Toxicity Conclusion References 2
21. Co-administration of nifedipine with # mg acetylsalicylic acid, benazepril, candesartancilexetil, doxasozine, omeprazole, orlistat, pantoprazole, ranitidine, rosiglitazone or triamterene/hydrochlorothiazide does not affect the pharmacokinetics of nifedipine
22. The pharmacokinetics of methoxy polyethylene glycol-epoetin beta were studied in healthy volunteers and in anaemic patients with CKD including patients on dialysis and not on dialysis
23. Buprenorphine/Naloxone Buccal Film Monograph Updated version may be found at www.pbm.va.gov or vaww.pbm.va.gov 2 Pharmacokinetics The main difference between buprenorphine / naloxone Buccal film and sublingual tablets is a
24. At simulatedin vivo conditions with constantly decreasing concentrations mimickingin vivo pharmacokinetics, synergy was detected against the beta-lactamase-producing strains tested, although the activity against the more resistantK. aerogenes strains was low.
25. Ideal Body Weight & Adjusted Body Weight Ideal body weight (IBW) and Adjusted body weight are frequently used clinically to adjust drug dosing, help estimate renal function and the pharmacokinetics in morbidly obese patients
26. In the population pharmacokinetic analysis of the phase # studies, the effect of the most frequently used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen, acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was explored
27. Pharmacokinetics and Barbiturates: Introduction and Overview: Barbiturates: Although barbituric acid was the first Barbiturate synthesized over hundred years ago, thiopental (Pentothal) has been clinical use for about 70 years in its use mark the beginning of IV anesthesia
28. TABLE OF CONTENTS 1 PRODUCT AND SUBMISSION INFORMATION 2 NOTICE OF DECISION 3 SCIENTIFIC AND REGULATORY BASIS FOR DECISION 3.1 Quality Basis for Decision 3.1.1 Drug Substance (Medicinal Ingredient) 3.1.2 Drug Product 3.1.3 Facilities and Equipment 3.1.4 Adventitious Agents Safety Evaluation 3.1.5 Conclusion 3.2 Non-clinical Basis for Decision 3.2.1 Pharmacodynamics 3.2.2 Pharmacokinetics 3.2.3 Toxicology 3.2.4 Summary and Conclusion 3.3 Clinical Basis for Decision 3.3.1 Pharmacodynamics 3.3.2 Pharmacokinetics 3.3.3 Clinical Efficacy 3.3.4 Clinical Safety 3.3.5 Outstanding Issues 3.4 Benefit/Risk Assessment and Recommendation 3.4.1 Benefit/Risk Assessment 3.4.2 Recommendation 4 SUBMISSION MILESTONES
29. A Phase 1 Study of AP01 (Aerodone, Pirfenidone Solution for Inhalation) Delivered via the PARI eFlow Nebulizer System in Healthy Volunteers, Smokers or Former Smokers with Decreased Lung Function, and Patients with Idiopathic Pulmonary Fibrosis (IPF) to determine pharmacokinetics, as well as the safety and tolerability in volunteers with a history of smoking with decreased lung function and
30. Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant medication on sildenafil pharmacokinetics when grouped as CYP#C# inhibitors (such as tolbutamide, warfarin, phenytoin), CYP#D# inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP# metabolism (such as rifampicin, barbiturates